November 20, 2026 · American journal of respiratory and critical care medicine · DOI: 10.1093/ajrccm/aamag613

Glucagon-Like Peptide-1 Agonists or Tezepelumab for Obesity-Associated Asthma: A Cohort Study.

Listen to this summary

This retrospective multi-institutional cohort study asked whether GLP-1-based medications (liraglutide, semaglutide, tirzepatide) offer respiratory benefits and weight loss comparable to the biologic tezepelumab in adults with obesity-associated, moderate-to-severe asthma without diabetes. Among 2,779 patients, tirzepatide initiators had a lower hazard of severe exacerbation than tezepelumab initiators (weighted HR 0.41), while semaglutide showed a similar hazard (weighted HR 0.99), and both tirzepatide and semaglutide led to faster >10% BMI reduction, less rescue inhaler use, and fewer respiratory encounters. The authors conclude that GLP-1-based therapies, particularly dual GLP-1/GIP agonists, may be comparable to biologic therapy in this population, though the observational design means randomized trials are needed to confirm these findings.

Kristen A Staggers, Charles Minard, Meredith C McCormack, Katherine N Cahill, Tianshi David Wu

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play